1. Wu J, Sakaguchi T, Takenaka K, Toyoda F, Tsuji K, Matsuura H, Horie M. A trafficking-deficient KCNQ1 mutation, T
2. Wu J, Mizusawa Y, Ohno S, Ding WG, Higaki T, Wang Q, Kohjitani H, Makiyama T, Itoh H, Toyoda F, James AF, Hancox JC, Matsuura H, Horie M. A hERG mutation E1039X produced a synergistic lesion on IKs together with KCNQ1-R
3. 宋苓苓，董超，翟晓晨，高洁，吴捷(通讯作者). 交感神经兴奋与1型长QT综合征（LQT1）. 心脏杂志. 2018; 30(6): 728-730
4. Wu J, Ohno S, Ding WG, Chao D, LL Song, Matsuura H, Horie M. Who is the pathogenic culprit? A LQTS family with three compound genetic mutation. J Am Coll Cardiol. 2018; 72(16):C170.(29th Great Wall International Congress of Cardiology (GW-ICC))（SCI收录）
5. Hirose S, Makiyama T, Melgari D, Wu J, Yokoi F, Wuriyanghai Y, yamamoto Y, Kohjitani H,
Nishiuchi S, Harita T, Hayano M, Yoshimoto J, Ohno S, Yoshida Y, Horie M, Kimura T. Propranolol
Inhibits Late Sodium Current in Long-QT Syndrome Type 3 Human Induced Pluripotent Stem Cell-
drived Myocyte Model. Circulation. 2017; 136(Suppl 1): A15660. (
6. Wu J(通讯作者), Ding WG, Horie M. Molecular pathogenesis of long QT syndrome
type 1 (review). J Arrhythm. 2016; 32:381.（SCI收录）
7. 翟晓晨, 吴捷(通讯作者). 三七总皂苷对脑缺血/再灌注损伤保护机制的研究进展.
中国药学杂志. 2016; 151: 24-27.
8. 董超，高洁，翟晓晨，吴捷(通讯作者). Kv1.5钾离子通道阻滞剂的研究进展. 中国药理学与毒
理学杂志. 2016;30:1097-1101.
9. Wu J, Naiki N, Ding WG, Ohno S, Kato K, Zang WJ, Matsuura H, Horie M. A Molecular
Mechanism for Adrenergic-induced Long QT Syndrome. J Am Coll Cardiol. 2014;
63(8): 819. (IF：16.503)
10.Zhou J, Ding WG,Makiyama T, Miyamoto A, Matsumoto Y, Kimura H, Tarutani Y,
Zhao J, Wu J (通讯作者), Zang WJ, Matsuura H, Horie M. A novel HCN4 mutation,
G1097W, is associated with atrioventricular block. Circ J. 2014; 78(4): 938.(IF：3.96）
11.Wu J, Ding W-G, Matsuura H, Tsuji K, Zang W-J, Horie M. Inhibitory actions of the
phosphatidylinositol 3-kinase inhibitor LY294002 on the human Kv1.5 channel.
Br J Pharmacol. 2009; 156:377. (IF：5.20)
12.Wu J, W Shimizu, W-G Ding, Ohno S, Toyoda F, Itoh H, W-J Zang, Miyamoto Y,
Kamakura S, Matsuura H, Nademanee K, Brugada J, Brugada P, Brugada R, Vatta M,
Towbin JA, Antzelevitch C, Horie M. KCNE2 Modulation of KV4.3 Current and
its Potential Role in Fatal Rhythm Disorders. Heart Rhythm 2010; 7:199. (IF：5.05)
13.Wu J, Ding WG, Matsuura H, Horie M. Regulatory mechanisms underlying the
modulation of GIRK1/GIRK4 heteromeric channels by P2Y receptors. Pflugers Arch.
2012; 464:625. (IF：4.87)
14.Nakajima T, Wu J (并列第一作者), Kaneko Y, Ashihara T, Ohno S, Irie T, Ding WG,
Matsuura H, Kurabayashi M, Horie M. KCNE3 T4A as the genetic basis of brugada-
pattern electrocardiogram. Circ J. 2012; 76: 2763. (IF：3.58)
15.Wu J, Ding WG,Zhao J,Zang WJ, Matsuura H,Horie M. Irbesartan mediated AT1
receptor blockade attenuates hyposmostic-induced enhancement of IKs current and
prevents shortening of action potential duration in atrial myocytes. J Renin
Angiotensin Aldosterone Syst. 2014;15: 341-347 (IF:2.4).
16.16. Qin W, Li YH, Tong J, Wu J, Dong C, Li HJ, Lu X, He CX, Zhou X, Li PQ, Meng G, Wu SP, Cao HL. Rational design and synthesis of 3-Morpholine linked aromatic-lmino-1H-indoles as novel Kv1.5 channel inhibitors sharing vasodilation effects. Rational design and synthesis of 3-Morpholine linked aromatic-lmino-1H-indoles as novel Kv1.5 channel inhibitiors sharing vasodilation effects. Front. Mol. Biosci. 2022; 8: 805594. doi: 10.3389/fmolb.2021.805594 (IF: 5.246)
17. Hirose S, Makiyama T, Melgari D, Yamamoto Y, Wuriyanghai Y, Yokoi F, Nishiuchi
S, Harita T, Hayano M, Kohjitani H, Gao J, Kashiwa A, Nishikawa, Wu Jie,
Yoshimoto J, Chonabayashi K, Ohno S, Yoshida Y, Horie M, Kimura T. Propranolol
attenuates late sodium current in a long TQ syndrome type 3-human induced
pluripotent stem cell model. Front Cell Dev Biol. 2020; 8: 761. （SCI收录，IF: 5.186）
18.Itoh H, Crotti L, Aiba T, Spazzolini C,Denjoy I, Fressart V, Hayashi
K, Nakajima T, Ohno S, Makiyama T, Wu J, Hasegawa K,Mastantuono E, Dagradi
F, Pedrazzini M, Yamagishi M, Berthet M,Murakami Y, Shimizu W, Guicheney P,
Schwartz PJ, Horie M. The genetics underlying acquired long QT syndrome:
impact for genetic screening.Eur Heart J. 2016; 37:1456-1464. (IF：19.651)
20.Wang Q, Ohno S, Ding WG, Fukuyama M, Miyamoto A, Itoh H, Makiyama T, Wu J, et al. Phenotype variability in patients carrying KCNJ2 mutations. Cardiovasc Electrophysiol. 2014;25(5):522. (IF：3.48)
21.Kimura H, Zhou J, Kawamura M, Itoh H, Mizusawa Y, Ding WG, Wu J,et al. Phenotype variability in patients carrying KCNJ2 mutations.Circ Cardiovasc Genet. 2012; 5: 344. (IF：6.73)
22.Li P, Ninomiya H, Kurata Y, Kato M, Miake J, Yamamoto Y, Igawa O,Nakai A, Higaki K, Toyoda F, Wu J, et al. Reciprocal control of hERG stability by Hsp70 and Hsc70 with implication for restoration of LQT2 mutant stability. Circ Res. 2011; 108: 458. (IF：11.86)
23.Itoh H, Oka Y, Ding WG, Sakaguchi T, Kimura H, Mizusawa Y, Miyamoto A, Wu J, Ohno S, Makiyama T, Ito M, Matsuura H, Horie M. Latent genetic backgrounds and molecular pathogenesis in acquired long QT syndrome with distinct arrhythmic triggers. Circulation. 2010; 122(Suppl 21): A10441.(Meeting Abstract)（SCI收录）
24.Gong YZ, Ding WG, Wu J, Tsuji K, Horie M, Matsuura H. Cinnamyl-3,4-dihydroxy-α-cyanocinnamate and nordihydroguaiaretic acid inhibit human Kv1.5 currents independently of lipoxygenase. Eur J Pharmacol.
2008; 600:18. (IF：2.79)
25.Lu J, Zhu SM, Zang WJ, Xu XL, Wu J, Horie M, et al. Protective mechanism of adenosine to the rat arterial endothelial dysfunction induced by hydrogen peroxide. Biol Pharm Bull. 2007; 30:1206. (IF：2.00)
26.Nagaoka I, Matsui K, Ueyama T, Kanemoto M, Wu J, Horie M, et al.A novel mutation of plakophilin-2 associated with arrhythmogenic right ventricular cardiomyopathy. Circ J. 2006; 70:933. (IF：3.58)
